Drug and alcohol review
September 1, 2022
Lukas A Basedow, Sören Kuitunen-Paul
42 citations
People most often use serotonergic psychedelics (hallucinogens) to expand their awareness, such as to increase self-knowledge, promote spiritual development, or satisfy curiosity. This motive appeared in 78% of the 37 studies reviewed, followed by coping (67%) and enhancement (57%). The pattern held across different types of psychedelics, different cultural backgrounds, and both quantitative and qualitative research, with no significant changes from 1967 to 2020. To reduce potential harms, harm-reduction services might offer non-drug ways to fulfill the desire for expanded awareness. Future research should examine motives for specific psychedelics.
Addiction Science & Clinical Practice
September 4, 2022
Lukas Andreas Basedow, Melina Felicitas Wiedmann, Veit Roessner et al.
17 citations
Adolescent patients with both post-traumatic stress disorder (PTSD) and substance use disorders (SUDs) reported more frequent past-year use of MDMA (ecstasy) than those with SUD alone or with traumatic experiences but no current PTSD. No such differences appeared for tobacco, alcohol, cannabis, or stimulants. The link between PTSD and higher MDMA use was partly explained by using the drug to cope with mental health symptoms. This suggests a specific coping mechanism for MDMA, possibly due to its unique psychoactive effects, rather than a general pattern of self-medication across all substances.
European Journal of Psychotraumatology
January 1, 2021
L. Basedow, Sören Kuitunen-Paul, M. Wiedmann et al.
15 citations
Adolescents with both a substance use disorder and probable post-traumatic stress disorder report more frequent use of MDMA (ecstasy) than those without PTSD, and they start using substances at a younger age. PTSD symptoms, especially avoidance, appear before first MDMA use, which begins on average 2.2 years after PTSD onset. The association between MDMA use and avoidance symptoms may reflect an attempt to reduce those symptoms or a consequence of regular MDMA use.
Frontiers in Psychiatry
January 21, 2022
Melina Wiedmann, Sören Kuitunen-Paul, Lukas A. Basedow et al.
5 citations
Among adolescent psychiatry outpatients with substance use disorder, attenuated psychotic symptoms were linked to MDMA (ecstasy) use and trauma history, but not to cannabis use. In a sample of 46 adolescents, 35% reported using MDMA in addition to cannabis. Statistical analysis showed that MDMA use and trauma history were each associated with more psychotic-like symptoms, while cannabis use, gender, and birth complications were not. The authors suggest that cannabis may increase psychosis risk only after longer use or when combined with other factors like trauma. Clinicians should screen for psychotic symptoms in adolescents who use both MDMA and cannabis.